Results 111 to 120 of about 35,836 (258)

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

, 2012
The brain tumor glioblastoma multiforme (GBM) is among the most lethal forms of human cancer. Here, we report that a small subset of GBMs (3.1%; 3 of 97 tumors examined) harbor oncogenic chromosomal translocations that fuse in-frame the tyrosine kinase ...
Riccardi, Riccardo
core   +2 more sources

Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne, Shomik Sengupta, Alison Y. Zhang, Niara Oliveira, Manish I. Patel, Ian Vela, Ian D. Davis   +6 more
wiley   +1 more source

Supplementary Figure 2 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors

, 2017
c-Myc downregulation is essential for FGFR inhibition caused growth arrest in FGFR-addicted cells.
Min Huang (161268), Jian Ding (163402), Hongyan Liu (142625), Yanyan Shen (7302266), Aijun Shen (4257868), Meiyu Geng (163413), Hui Chen (28597), Yi Chen (38576), Jing Ai (271316), Xinyi Wang (559030), Xia Peng (1601440)   +10 more
core   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI

Frontiers in Immunology
BackgroundTraumatic brain injury (TBI) induces an acute reactive state of microglia, which contribute to secondary injury processes through phagocytic activity and release of cytokines.
Rida Rehman, Rida Rehman, Albrecht Froehlich, Florian olde Heuvel, Lobna Elsayed, Tobias Boeckers, Tobias Boeckers, Markus Huber-Lang, Cristina Morganti-Kossmann, Cristina Morganti-Kossmann, Francesco Roselli, Francesco Roselli   +11 more
doaj   +1 more source

Immunohistochemical staining of FGFR-2 (A-C).

, 2015
A, FGFR-2 positivity in transformed cases of Leukoplakia with dysplasia X 200. B, FGFR-2 positivity in transformed case of OSMF in fibrosis area X 100. C, FGFR-2 positivity in OSCC X 100.
Vikram Bhatia (406012), Seema Nayak (813016), Annu Makker (813017), Saumya Chandra (813018), Sandeep Kumar (145759), Madhu Mati Goel (473426), S. P. Agarwal (813019)   +6 more
core   +1 more source

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

Brain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg, Simone Schmid, Arend Koch, Eilís Perez, Daniel Teichmann, Martin Misch, Anna‐Gila Karbe, Susanne Ukrow, Patrick N. Harter, Ruth M. Stassart, Peter Vajkoczy, Julia Onken, David Capper   +15 more
wiley   +1 more source

532 Evaluating fibroblast growth factor receptor (FGFR) pathway mRNA expression and protein activation in cholangiocarcinoma tumors

Journal of Clinical and Translational Science
Objectives/Goals: Personalized cancer therapy based on genomic testing is advancing patient care. Genomic alterations in fibroblast growth factor receptor (FGFR) predict response to FGFR inhibitors; however, the role of RNA expression and protein ...
Leah Stein, Julie W. Reeser, Michele R. Wing, Eric Samorodnitsky, Anoosha Paruchuri, Amy Smith, Thuy Dao, Zachary Risch, Emanuel F. Petricoin, Sameek Roychowdhury   +9 more
doaj   +1 more source

LAMC2+ Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis

Cancer Science, EarlyView.
This study identified LAMC2+ epithelial cells through single‐cell sequencing and found that high expression of LAMC2 is associated with the malignant progression of bladder cancer. HdWGCNA and transcriptome sequencing revealed the SerpinB3/STAT3/CD44 axis. Diosmetin was selected as a potential LAMC2 inhibitor.
Yutong Chen, Yunzhong Jiang, Zezhong Yang, Minxuan Jing, Wentai Wu, Jiale He, Lu Wang, Minghai Ma, Yaodong Zhang, Min Wang, Jianpeng Li, Yuanchun Pu, Bingliang He, Yanjia Liu, Kaibo Mi, Hang Liu, Mengzhao Zhang, Jinhai Fan   +17 more
wiley   +1 more source

Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.

PLoS ONE, 2014
BackgroundFibroblast growth factor receptor (FGFR) gene amplification has been reported in different types of cancer. We performed an up-to-date meta-analysis to further characterize the prognostic value of FGFR gene amplification in patients with cancer.
Jinjia Chang, Xinyang Liu, Shanshan Wang, Zhe Zhang, Zheng Wu, Xiaowei Zhang, Jin Li   +6 more
doaj   +1 more source